Advertisement

Blue light photodynamic therapy with 5-aminolevulinic acid in refractory mycosis fungoides: A prospective, open-label study

Published:January 22, 2021DOI:https://doi.org/10.1016/j.jaad.2021.01.053
      To the Editor: Mycosis fungoides (MF) is the most common primary cutaneous lymphoma.
      • Kim Y.H.
      • Liu H.L.
      • Mraz-Gernhard S.
      • Varghese A.
      • Hoppe R.T.
      Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.
      While typically indolent, refractory and progressive disease occurs in approximately 20% and is associated with significant morbidity and higher mortality.
      • Kim Y.H.
      • Liu H.L.
      • Mraz-Gernhard S.
      • Varghese A.
      • Hoppe R.T.
      Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.
      ,
      • Zackheim H.S.
      • Amin S.
      • Kashani-Sabet M.
      • McMillan A.
      Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients.
      We conducted the first prospective trial, to our knowledge, to assess blue light photodynamic therapy (PDT) with 5-aminolevulinic acid (ALA) in MF.
      To read this article in full you will need to make a payment
      AAD Member Login
      AAD Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kim Y.H.
        • Liu H.L.
        • Mraz-Gernhard S.
        • Varghese A.
        • Hoppe R.T.
        Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.
        Arch Dermatol. 2003; 139: 857-866
        • Zackheim H.S.
        • Amin S.
        • Kashani-Sabet M.
        • McMillan A.
        Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients.
        J Am Acad Dermatol. 1999; 40: 418-425
        • Fernandez-Guarino M.
        • Harto A.
        • Perez-Garcia B.
        • Montull C.
        • De Las Heras E.
        • Jaen P.
        Plaque-phase mycosis fungoides treated with photodynamic therapy: results from 12 patients.
        Actas Dermosifiliogr. 2010; 101 ([in Spanish]): 785-791
        • Quereux G.
        • Brocard A.
        • Saint-Jean M.
        • et al.
        Photodynamic therapy with methyl-aminolevulinic acid for paucilesional mycosis fungoides: a prospective open study and review of the literature.
        J Am Acad Dermatol. 2013; 69: 890-897
        • Olsen E.A.
        • Whittaker S.
        • Kim Y.H.
        • et al.
        Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the cutaneous lymphoma task force of the European Organisation for Research and Treatment of Cancer.
        J Clin Oncol. 2011; 29: 2598-2607